
News|Articles|November 1, 2012
From the European Society for Medical Oncology 2012 Congress: Additional safety, tolerability data for tivozanib versus sorafenib in metastatic RCC shows fewer adverse events
New data demonstrating the safety and tolerability profile of tivozanib versus sorafenib in the first-line setting for patients with metastatic renal cell carcinoma (RCC), was presented at ESMO's 2012 Congress.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Patient-facing EHR tool improves lung cancer screening identification
2
A jump in shingles after first Shingrix dose but the risk is transient, study finds
3
DOD-funded study explores metformin as potential therapy for IPF
4
How California is rewriting the PBM playbook
5




















































